Announced Date: 2025-02-19 (February 19, 2025)
Asset Name: SYS6005 (RB-164)
Licensor: CSPC Pharmaceutical Group (China) together with its subsidiaries CSPC Megalith
Licensee (Buyer): Radiance Biopharma (US)
.
Asset Modality: ADC (antibody drug conjugate)
Asset Target: recombinant anti-human receptor tyrosine kinase-like orphan receptor 1 (ROR1)
Potential Indication: solid tumors
Current Stage:
.
Scope of Authority:
CSPC Megalith has granted Radiance exclusive worldwide rights for the development and commercialization of SYS6005 in the United States, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia, and Canada (the ‘‘Territory’’)
.
Deal Detail:
CSPC Megalith will receive
Upfront payment of $15 million,
Development and regulatory milestone payments up to $150 million,
Sales milestone payments of up to $1.075 billion,
Total up to $1.24 billion.
Plus tiered royalties based on annual net sales of the Product in the Territory.
.
